Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Mar 9, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring how to manage early-onset fetal growth restriction, a condition where a baby is not growing as expected during pregnancy. The study will involve 340 pregnant women who are between 26 and 31 weeks along and have a measured fetal weight that is smaller than normal (less than the 10th percentile). Participants will be randomly assigned to one of two groups: one group will receive standard care based on ultrasound blood flow measurements (Doppler), while the other group will use a new method that involves specific blood test results to help decide how often ultrasounds are done and when to plan for delivery.

To be eligible for this trial, women must be at least 18 years old and have a single baby (not twins or more) with a low fetal weight during the specified weeks of pregnancy. They should also have a confirmed gestational age from an early pregnancy scan or from fertility treatment. Unfortunately, women with serious fetal problems or who are not willing to participate cannot join the study. This trial is not yet recruiting participants but aims to find better ways to care for pregnancies affected by growth issues.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women of at least 18 years old
• • Singleton pregnancy
• • Ultrasonographic EFW ≤10th percentile between 26+0 and 31+6 weeks of gestation
• • Gestational age confirmed by fetal crown-rump length measurement during the first trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates.
• Exclusion Criteria:
• • Major fetal malformations or genetic disorders
• • Fetal death
• • Refusal to give informed consent
• • Stage IV FGR